reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Summary

The bill amends South Dakota’s controlled‑substance schedule to exempt FDA‑approved crystalline polymorph psilocybin drug products from the Schedule I list, placing them under Schedule IV. This change affects manufacturers, prescribers and patients who may use such psilocybin medicines, aligning state law with the federal FDA approval while keeping regulatory oversight. It is intended to allow medical use of psilocybin while maintaining control measures.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share